OSI Pharmaceuticals Initiates Clinical Development Program For Anti-Obesity Candidate

New cases in Pous 2064, HIV = 175, AIDS = 26, Death = 2. HIV rate is very high in Housewives than sex workers in Nepal ! ! ! HIV status in Nepal till 2005: Total Adult=70000, Adult Prevalence (15-49)=0.55%, Number of Women (15-49) LWHA=15,310 (22%), HIV Prevalence rate in IDUs=32.7%, HIV prevalence rate in sex worker=3.8%, HIV prevalence rate in client of SW=2.1%. The latest U.N. report shows that 65 million people have been infected with HIV since it was first identified 25 years ago. Twenty five million people have died of AIDS.

Welcome to the xenoMED, an online Medical Community where Academically sound, Professionally conscious and Socially responsible Medical Students, Doctors & Health Professionals interact with each other globally.

Medicine is the only profession that incessantly tries to destroy its own existence. Howsoever you may be associated with basic and/or clinical medicine - student or professor, physician or surgeon, undergraduate or postgraduate - this is your place to share your knowledge, and learn more. Just get the message across!

You are currently viewing our communiy as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, Join Our Medical Cummunity Today!

If you have any problems with the registration process or your account login, please contact us.

		xenoMED > News Room > Health News > Medical News Today
OSI Pharmaceuticals Initiates Clinical Development Program For Anti-Obesity Candidate

(#1 (permalink))

News is Offline

Senior Member

Posts: 677

Thanks: 0

Thanked 35 Times in 35 Posts

Join Date: Sep 2007

OSI Pharmaceuticals Initiates Clinical Development Program For Anti-Obesity Candidate - 21-06-2008, 03:11 AM

OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced that it has initiated the first-in-human clinical study of its development compound PSN602. Discovered by OSI's diabetes and obesity team, PSN602 is an oral dual serotonin and norepinephrine reuptake inhibitor and 5-HT1A agonist, being developed for the treatment of obesity.

More...

« Scientists From The University Of Navarra Find 5 Genes Involved In The Metastasis Of | Metabasis Announces Promising Results From Its Phase 1b Clinical Trial For MB07811, I »

Thread Tools	Search this Thread
Show Printable Version Email this Page	Search this Thread: Advanced Search
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Trackbacks are On Pingbacks are On Refbacks are On

Similar Threads
Thread	Thread Starter	Forum	Replies	Last Post
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial Program Of APD791 For The Trea	Angel	Medical News Today	0	19-07-2007 12:30 AM
Acute Onset Fever & Abdominal Pain in a 44yrs /F	JNUS	Clinical Vignette	2	27-06-2007 09:43 AM
Manhattan Pharmaceuticals Expands Phase 2a Obesity Clinical Trial Sites To US	Angel	Medical News Today	0	09-11-2006 12:20 AM
IMG friendly Internal medicine hospitals	usmlelover	Residency	0	06-04-2006 06:12 AM

Hosted and Maintained by: